Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients

Ma et al., AACR Annual Meeting 2022

Apr 2022

Source PDF All Studies Meta AnalysisMeta

Review of the mechanisms of action of proxalutamide for COVID-19, and In Vitro results showing that proxalutamide inhibited SARS-CoV-2 wild type, alpha and delta variants, with IC₅₀ of 69, 48 and 39nM. Only the abstract is currently available.

2 preclinical studies support the efficacy of proxalutamide for COVID-19:

2 In Vitro studies Ma, Qiao

Important missing comments or errors? Let us know.

1. Ma et al., Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients, AACR Annual Meeting 2022, www.abstractsonline.com/pp8/#!/10517/presentation/18533.abstractsonline.com.

2. Qiao et al., Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response, PNAS, doi:10.1073/pnas.222180912.pnas.org, doi.org.

Ma et al., 8 Apr 2022, peer-reviewed, 12 authors.

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

This Paper Proxalutamide All

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0